Improving survival trends in primary myelofibrosis: An international study

Francisco Cervantes, Brigitte Dupriez, Francesco Passamonti, Alessandro M. Vannucchi, Enrica Morra, John T. Reilly, Jean Loup Demory, Elisa Rumi, Paola Guglielmelli, Elisa Roncoroni, Ayalew Tefferi, Arturo Pereira

Research output: Contribution to journalArticlepeer-review

80 Scopus citations


Purpose: Despite the lack of major improvements in the treatment of primary myelofibrosis (PMF), there are recent indications that the survival of patients might have increased over the years. This study was aimed at ascertaining whether survival prolongation has actually occurred in PMF. Patients and Methods: A total of 802 patients diagnosed with PMF in four European countries were compared for the presentation of features and survival according to the diagnostic periods 1980 to 1995 (n = 434) and 1996 to 2007 (n = 368); relative survival was estimated for the two groups. Results: Patients diagnosed between 1996 and 2007 more often had constitutional symptoms (31% v 23%) but a lower incidence of marked anemia (31% v 39%), leukocytosis greater than 25 X 109/L (9% v 13%), and blood blasts (27% v 33%); risk distribution was comparable between the two groups. Median survival was 4.6 years (95% CI, 4.0 to 5.1) for patients from 1980 to 1995 and 6.5 years (95% CI, 5.5 to 7.4) for patients from 1996 to 2007 (P < .001). The latter group of patients showed improved relative survival, especially for women, patients younger than age 65 years, and patients with low or intermediate-1-risk disease. Rates of PMF-attributable mortality at 5 and 10 years were significantly lower in the second period; this reduction in disease-specific mortality occurred across all patient subgroups, except in intermediate-2-risk or high-risk patients. Conclusion: Survival of PMF is steadily improving, except in patients in poor-risk categories. This observation must be taken into account at the time of evaluating the survival impact of newer therapies for PMF, which are currently being tested in these patient subpopulations.

Original languageEnglish (US)
Pages (from-to)2981-2987
Number of pages7
JournalJournal of Clinical Oncology
Issue number24
StatePublished - Aug 20 2012

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Improving survival trends in primary myelofibrosis: An international study'. Together they form a unique fingerprint.

Cite this